US REFORM HEALTHY FOR BRISBANE'S BIOLOGICS

US REFORM HEALTHY FOR BRISBANE'S BIOLOGICS

THE national biotechnology body says recent US health reforms will ‘change the game’ for Australian biologics companies, with patent life extension for products including vaccines and allergenics.

AusBiotech CEO Dr Anna Lavelle, says the US health reforms change the Hatch-Waxman Act, increasing biologic patent life extensions from five to 12 years.

“The game is changing and it means that some biologic technologies that may have been put in the drawer before will now have a more reasonable return on investment, factoring in longer times before generics get to the market,” she says.

“It could be significant because with the big pharma companies looking at their project pipelines, about 25 per cent of those in the pipeline are biologic and by 2025 it could grow to about 50 per cent.

“Before they had the two mistresses of speed and getting it right, but this takes the weight off significantly and that’s good news.”

She says while biotech companies will benefit because they will have more time to perfect their products, generics companies are looking at the situation ‘philosophically’.

For Brisbane-based Alchemia, the patent life extension will mean delays for some of its biologics products under development, dealing with the delivery of ‘super generics’ that can only be released once patent exclusivity expires.

CEO Dr Pete Smith (pictured), says the US health reform is good overall for the biotech sector but it’s ‘not a great sea change’, as increased access to pharmaceuticals will be partially offset by a push for affordability.

“Longer patent lives mean we will have to wait longer before we get to delivery on the market. The matter is that we’ll see patients able to receive drugs more widely, but there will be a push for affordability so the net value for pharmaceuticals will be quite neutral,” he says.

Help us deliver quality journalism to you.
As a free and independent news site providing daily updates
during a period of unprecedented challenges for businesses everywhere
we call on your support

Crypto staking: a new way to earn passive income
Partner Content
You may be familiar with traditional ways of earning passive income such as trading sto...
Etoro
Advertisement

Related Stories

John McGrath calls for calm as real estate company forecasts rise in earnings for FY22

John McGrath calls for calm as real estate company forecasts rise in earnings for FY22

Despite recent trading conditions proving disruptive for the reside...

Board exodus gathers pace at The Star after O’Neill resigns as chairman

Board exodus gathers pace at The Star after O’Neill resigns as chairman

The Star Entertainment Group (ASX: SGR) is now on the hunt for a ne...

Woolworths adds controlling stake in MyDeal to cart for $218 million

Woolworths adds controlling stake in MyDeal to cart for $218 million

Woolworths (ASX: WOW) is looking to enhance its online marketplace ...

Bendigo-based Apiam Animal Health saddles up with $13.8m acquisitions

Bendigo-based Apiam Animal Health saddles up with $13.8m acquisitions

Vet services business Apiam Animal Health (ASX: AHX) has gone ...